|
|
ASH 2011: Dr. Jagannath - Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 2-3 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study
Sundar Jagannath, MD
Mount Sinai Medical Center
New York, New York, USA
|
|
|
12.06.11 |
To view the video full screen, click on the small
 button next to the volume control in the
lower right hand corner.
|
 related articles
|
|
print